Conference Coverage
Conference Coverage
Think duration, not dose, when managing bleeding with non–factor replacements
PRAGUE – The duration of treatment is more strongly linked to thromboembolism than dose magnitude, according to Dr. Andreas Tiede.
Conference Coverage
SEER data: Abiraterone acetate may up mortality risk in prostate cancer patients with CVD
A review of SEER-Medicare linked data suggests an increased mortality risk with abiraterone acetate treatment in prostate cancer patients with vs...
Conference Coverage
Diet appears to play an important role in response to anti-PD-1 cancer immunotherapy
Diet appears to affect response to anti-PD-1 cancer immunotherapy, likely by its effect on the gut microbiome.
Conference Coverage
NILE: Liquid biopsy bests tissue testing for targetable mutations in NSCLC
Liquid biopsy was more effective and faster than tissue-based genotyping for identifying targetable mutations in advanced NSCLC in the prospective...
Conference Coverage
Enzalutamide boosts ADT benefit in metastatic hormone-sensitive prostate cancer
SAN FRANCISCO – In findings that may ultimately change clinical practice, the phase 3 ARCHES trial has shown that adding the androgen receptor...
Conference Coverage
Emicizumab performs well in surgical setting
PRAGUE – Based on the experience in this small study, bleeding complications were most common during dental procedures.
Conference Coverage
Subcutaneous FVIIa marzeptacog alfa reduced bleeding days
PRAGUE – The treatment was well tolerated with no reports of thrombosis or antidrug antibodies detected.
Conference Coverage
Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML
HOUSTON – The effect was most pronounced in those with high pFLT3 inhibition on plasma inhibitor activity assay.
Conference Coverage
Padua variant factor IX gene shines in AMT-061
PRAGUE – Early data shows clinically meaningful factor IX activity in men with hemophilia B.
Conference Coverage
ZUMA-1 update: Axi-cel responses persist at 2 years
HOUSTON – Median duration of response and overall survival have not yet been reached in the pivotal CAR T-cell therapy trial.
Conference Coverage
Tivozanib has PFS benefit over sorafenib in hard-to-treat RCC
SAN FRANCISCO – In the TIVO-3 trial, tivozanib prolonged progression-free survival by about 2 months, compared with sorafenib, in patients with...